Clinical impact of fluvoxamine-mediated long QTU syndrome
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2012, Vol.68 (1), p.109-111 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 111 |
|---|---|
| container_issue | 1 |
| container_start_page | 109 |
| container_title | European journal of clinical pharmacology |
| container_volume | 68 |
| creator | Nia, Amir M. Dahlem, Kristina M. Gassanov, Natig Hungerbühler, Hansjörg Fuhr, Uwe Er, Fikret |
| description | |
| doi_str_mv | 10.1007/s00228-011-1091-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_913173597</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2550818971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-1d099054d5e2483dc2ed54fcbbcffbd220b3621c8c613c840fa21b14636b577d3</originalsourceid><addsrcrecordid>eNp1kEtLw0AQxxdRbK1-AC8SvK_O7CbZ7FGCLyiI0J6XZB8lJY-6m4j99qak6snTMMz_wfwIuUa4QwBxHwAYyyggUgSJVJyQOcacjVuMp2QOwJGmUsCMXISwBcBEAj8nM4YCeYJiTmReV22lizqqml2h-6hzkauHz-6raKrW0saaquitiequ3UTvq3UU9q3xXWMvyZkr6mCvjnNB1k-Pq_yFLt-eX_OHJdWcZz1FA1JCEpvEsjjjRjNrktjpstTOlYYxKHnKUGc6Ra6zGFzBsMQ45WmZCGH4gtxOuTvffQw29GrbDb4dK5VEjoInUowinETadyF469TOV03h9wpBHVipiZUaWakDK3Xw3ByDh3J889fxA2cUsEkQxlO7sf6v-f_Ub1ylctA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>913173597</pqid></control><display><type>article</type><title>Clinical impact of fluvoxamine-mediated long QTU syndrome</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Nia, Amir M. ; Dahlem, Kristina M. ; Gassanov, Natig ; Hungerbühler, Hansjörg ; Fuhr, Uwe ; Er, Fikret</creator><creatorcontrib>Nia, Amir M. ; Dahlem, Kristina M. ; Gassanov, Natig ; Hungerbühler, Hansjörg ; Fuhr, Uwe ; Er, Fikret</creatorcontrib><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-011-1091-7</identifier><identifier>PMID: 21713517</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Anti-Anxiety Agents - adverse effects ; Anti-Anxiety Agents - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Cognition Disorders - complications ; Epilepsy - complications ; ERG1 Potassium Channel ; Ether-A-Go-Go Potassium Channels - antagonists & inhibitors ; Female ; Fluvoxamine - adverse effects ; Fluvoxamine - therapeutic use ; Humans ; Letter to the Editors ; Long QT Syndrome - chemically induced ; Long QT Syndrome - physiopathology ; Long QT Syndrome - therapy ; Middle Aged ; Multiple Sclerosis - complications ; Obsessive-Compulsive Disorder - complications ; Obsessive-Compulsive Disorder - drug therapy ; Pharmacology/Toxicology ; Potassium Channel Blockers - adverse effects ; Potassium Channel Blockers - therapeutic use ; Schizophrenia - complications ; Serotonin Uptake Inhibitors - adverse effects ; Serotonin Uptake Inhibitors - therapeutic use ; Treatment Outcome</subject><ispartof>European journal of clinical pharmacology, 2012, Vol.68 (1), p.109-111</ispartof><rights>Springer-Verlag 2011</rights><rights>Springer-Verlag 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c338t-1d099054d5e2483dc2ed54fcbbcffbd220b3621c8c613c840fa21b14636b577d3</citedby><cites>FETCH-LOGICAL-c338t-1d099054d5e2483dc2ed54fcbbcffbd220b3621c8c613c840fa21b14636b577d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-011-1091-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-011-1091-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21713517$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nia, Amir M.</creatorcontrib><creatorcontrib>Dahlem, Kristina M.</creatorcontrib><creatorcontrib>Gassanov, Natig</creatorcontrib><creatorcontrib>Hungerbühler, Hansjörg</creatorcontrib><creatorcontrib>Fuhr, Uwe</creatorcontrib><creatorcontrib>Er, Fikret</creatorcontrib><title>Clinical impact of fluvoxamine-mediated long QTU syndrome</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><subject>Anti-Anxiety Agents - adverse effects</subject><subject>Anti-Anxiety Agents - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cognition Disorders - complications</subject><subject>Epilepsy - complications</subject><subject>ERG1 Potassium Channel</subject><subject>Ether-A-Go-Go Potassium Channels - antagonists & inhibitors</subject><subject>Female</subject><subject>Fluvoxamine - adverse effects</subject><subject>Fluvoxamine - therapeutic use</subject><subject>Humans</subject><subject>Letter to the Editors</subject><subject>Long QT Syndrome - chemically induced</subject><subject>Long QT Syndrome - physiopathology</subject><subject>Long QT Syndrome - therapy</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - complications</subject><subject>Obsessive-Compulsive Disorder - complications</subject><subject>Obsessive-Compulsive Disorder - drug therapy</subject><subject>Pharmacology/Toxicology</subject><subject>Potassium Channel Blockers - adverse effects</subject><subject>Potassium Channel Blockers - therapeutic use</subject><subject>Schizophrenia - complications</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kEtLw0AQxxdRbK1-AC8SvK_O7CbZ7FGCLyiI0J6XZB8lJY-6m4j99qak6snTMMz_wfwIuUa4QwBxHwAYyyggUgSJVJyQOcacjVuMp2QOwJGmUsCMXISwBcBEAj8nM4YCeYJiTmReV22lizqqml2h-6hzkauHz-6raKrW0saaquitiequ3UTvq3UU9q3xXWMvyZkr6mCvjnNB1k-Pq_yFLt-eX_OHJdWcZz1FA1JCEpvEsjjjRjNrktjpstTOlYYxKHnKUGc6Ra6zGFzBsMQ45WmZCGH4gtxOuTvffQw29GrbDb4dK5VEjoInUowinETadyF469TOV03h9wpBHVipiZUaWakDK3Xw3ByDh3J889fxA2cUsEkQxlO7sf6v-f_Ub1ylctA</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Nia, Amir M.</creator><creator>Dahlem, Kristina M.</creator><creator>Gassanov, Natig</creator><creator>Hungerbühler, Hansjörg</creator><creator>Fuhr, Uwe</creator><creator>Er, Fikret</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>2012</creationdate><title>Clinical impact of fluvoxamine-mediated long QTU syndrome</title><author>Nia, Amir M. ; Dahlem, Kristina M. ; Gassanov, Natig ; Hungerbühler, Hansjörg ; Fuhr, Uwe ; Er, Fikret</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-1d099054d5e2483dc2ed54fcbbcffbd220b3621c8c613c840fa21b14636b577d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-Anxiety Agents - adverse effects</topic><topic>Anti-Anxiety Agents - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cognition Disorders - complications</topic><topic>Epilepsy - complications</topic><topic>ERG1 Potassium Channel</topic><topic>Ether-A-Go-Go Potassium Channels - antagonists & inhibitors</topic><topic>Female</topic><topic>Fluvoxamine - adverse effects</topic><topic>Fluvoxamine - therapeutic use</topic><topic>Humans</topic><topic>Letter to the Editors</topic><topic>Long QT Syndrome - chemically induced</topic><topic>Long QT Syndrome - physiopathology</topic><topic>Long QT Syndrome - therapy</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - complications</topic><topic>Obsessive-Compulsive Disorder - complications</topic><topic>Obsessive-Compulsive Disorder - drug therapy</topic><topic>Pharmacology/Toxicology</topic><topic>Potassium Channel Blockers - adverse effects</topic><topic>Potassium Channel Blockers - therapeutic use</topic><topic>Schizophrenia - complications</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nia, Amir M.</creatorcontrib><creatorcontrib>Dahlem, Kristina M.</creatorcontrib><creatorcontrib>Gassanov, Natig</creatorcontrib><creatorcontrib>Hungerbühler, Hansjörg</creatorcontrib><creatorcontrib>Fuhr, Uwe</creatorcontrib><creatorcontrib>Er, Fikret</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nia, Amir M.</au><au>Dahlem, Kristina M.</au><au>Gassanov, Natig</au><au>Hungerbühler, Hansjörg</au><au>Fuhr, Uwe</au><au>Er, Fikret</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical impact of fluvoxamine-mediated long QTU syndrome</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2012</date><risdate>2012</risdate><volume>68</volume><issue>1</issue><spage>109</spage><epage>111</epage><pages>109-111</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>21713517</pmid><doi>10.1007/s00228-011-1091-7</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2012, Vol.68 (1), p.109-111 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_journals_913173597 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Anti-Anxiety Agents - adverse effects Anti-Anxiety Agents - therapeutic use Biomedical and Life Sciences Biomedicine Cognition Disorders - complications Epilepsy - complications ERG1 Potassium Channel Ether-A-Go-Go Potassium Channels - antagonists & inhibitors Female Fluvoxamine - adverse effects Fluvoxamine - therapeutic use Humans Letter to the Editors Long QT Syndrome - chemically induced Long QT Syndrome - physiopathology Long QT Syndrome - therapy Middle Aged Multiple Sclerosis - complications Obsessive-Compulsive Disorder - complications Obsessive-Compulsive Disorder - drug therapy Pharmacology/Toxicology Potassium Channel Blockers - adverse effects Potassium Channel Blockers - therapeutic use Schizophrenia - complications Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - therapeutic use Treatment Outcome |
| title | Clinical impact of fluvoxamine-mediated long QTU syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T05%3A17%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20impact%20of%20fluvoxamine-mediated%20long%20QTU%20syndrome&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Nia,%20Amir%20M.&rft.date=2012&rft.volume=68&rft.issue=1&rft.spage=109&rft.epage=111&rft.pages=109-111&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-011-1091-7&rft_dat=%3Cproquest_cross%3E2550818971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=913173597&rft_id=info:pmid/21713517&rfr_iscdi=true |